drugset / Trial / NCT00650299

Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg

NCT00650299

Phase 1 Completed 21 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's alprazolam Extended-release 3 mg tablets to Pharmacia \& Upjohn's Xanax XR® 3 mg tablets following a single, oral 3 mg (1 x 3 mg) dose administered under fed conditions.

Timeline

Start
2004-08
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 3 mg Oral

Indications

No indication recorded.